Current partner codePEPTIDESDE
NCT02892942·Phase 4·INTERVENTIONAL

NATural Ovarian Stimulation

Status

Completed

Phase

Phase 4

Enrollment

129

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

To overcome unsuitable effects of controlled ovarian hyperstimulation (COH )while maintaining large oocyte availability, investigators elaborated an innovative protocol (NATural Ovarian Stimulation) that dissociates E2 production from multiple follicle development. The purpose of this prospective, randomized trial is to demonstrate that, in a good prognosis IVF-ET population, the physiological E2 environment resulting from NATOS significantly improves IVF-ET outcome when compared to the conventional GnRH antagonist protocol.

Full detailed description

Controlled ovarian hyperstimulation (COH) seeks to improve IVF-ET results by increasing per-cycle oocyte and embryo availability. Yet, the coexistence of multiple preovulatory follicles engenders compulsory alterations in the endocrine milieu of the follicular phase. The most evident of them are the extremely high serum estradiol (E2) levels. The 10 to 15-fold increase in E2 levels as a result of COH has been shown to provoke unwanted consequences in both embryo quality and uterine receptivity. Therefore, investigators elaborated an innovative COH protocol (NATural Ovarian Stimulation) that aimed at dissociating E2 production from multiple follicle development. To obtain this effect, they virtually curtailed endogenous LH production by using GnRH antagonist doses as strong and frequent enough to maintain E2 levels around the physiological range during standard exogenous FSH-only administration. Given that high E2 levels are commonly reached in patients having a normal follicle endowment, NATOS should target this group of good prognosis IVF-ET candidates. Indeed, this new COH approach was first tested in a pilot study that included 15 good prognosis IVF-ET candidates, aged 25-35 years, who volunteered to undergo NATOS. 11 out of 15 patients achieved a pregnancy. These pilot results spurred them to conduct a prospective, randomized trial to demonstrate that, in a good prognosis IVF-ET population, the physiological E2 environment resulting from NATOS significantly improves IVF-ET outcome when compared to the conventional GnRH antagonist protocol.

Interventions

Treatment arms and agents.

DRUG

Gonal-F®

225 to 450 IU/d; from day 2 of menstrual cycle onward

DRUG

Cetrotide®

0.25 mg/day, starting on day 6 of Gonal-F®.

DRUG

Cetrotide®

1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG

Timeline

From registration to results.

  1. First posted

    Sep 8, 2016

  2. Study start

    Jan 13, 2017

  3. Primary completion

    Feb 8, 2019

  4. Study completion

    Feb 8, 2019

  5. Results posted

    Not reported

  6. Registry updated

    Apr 3, 2026

Outcomes

What the study measures.

Primary outcomes

Live birth obtained after IVF-ET

Time frame · 1 month post-partum

Live birth defined as delivery ≥ 22 weeks of amenorrhea

Secondary outcomes

Number of oocytes obtained

Time frame · At oocyte retrieval (14±8 days after start of treatment)

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
40 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * IVF-ET candidates (excluding PGD and oocyte donor); * Body mass index from 18 to 30 kg/m2; * Non smokers; * Regular menstrual cycles (25-35 days); * Presence of both ovaries; * Antral follicle count (follicles measuring from 3 to 10 mm in diameter) ranging from 10 to 30 on cycle days 2 to 4; * Serum AMH levels ranging from 0.5 to 5.0 ng/mL; * Normal endometrium at ultrasound (US) and/or hysteroscopy; * Informed consent signed Exclusion Criteria: * Iatrogenic ovarian insufficiency (surgery, radiotherapy, chemotherapy); * Uterine abnormalities as demonstrated by pelvic US and/or hysteroscopy; * Usual contra-indications for COH (cancer risk, blood coagulation disorders, etc) * Renal insufficiency

Study locations

1 registered sites.

France. Showing up to 24 locations stored in the fast local snapshot.

Hôpital Antoine Béclère

Clamart, France

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Cetrorelix.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.